Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Filings indexed 361 across all filing types
Latest filing 2022-11-24 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Regulatory Filings
2022-11-24 English
Next Day Disclosure Return
Regulatory Filings
2022-11-16 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
Regulatory Filings
2022-11-04 English
VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY NMPA FOR A PHASE IA/IB CLINICAL TRIAL OF JSKN003 FOR THE TREATMENT OF ADVANCED SOLID TUMORS
Regulatory Filings
2022-10-27 English
GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME
Regulatory Filings
2022-10-24 English
GRANT OF SHARE OPTIONS
Regulatory Filings
2022-10-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.